Skip to main content
. Author manuscript; available in PMC: 2016 Jul 7.
Published in final edited form as: Cell Metab. 2015 Jun 18;22(1):86–99. doi: 10.1016/j.cmet.2015.05.012

Figure 6. Effects of a human adapted FMD regimen in a pilot clinical trial.

Figure 6

A) Subjects were randomized to either the Fasting Mimicking Diet (FMD) or a control group. Subjects in the FMD cohort consumed the FMD for 5 consecutive days every month for 3 months and returned to normal diet in-between FMDs. Control subjects continued their normal diet. Measurements were performed prior to the diet (Baseline), immediately after the first FMD cycle (FMD) and during the recovery period after the 3rd cycle (FMD-RF). Subjects in the control group were evaluated within the same time frame as the FMD-RF subjects (End). B) Glucose (N= 19). C) β-hydroxybutyrate (FMD N= 19, Control N= 18). D) IGF-I (FMD N= 19, Control N= 18) and E) IGFBP-I (FMD N= 19, Control N= 17). F) Body weight (N= 19). G) Trunk fat (FMD N= 18, Control N= 19) and H) Lean body mass evaluated by dual energy x-ray absorptiometry. I) C-reactive protein (CRP; FMD N= 19, Control N= 18) levels of all subjects (left panels) and subjects in the average or high risk group for heart disease (N= 8; right panel). J) Percentage of lin−CD184+CD45− mesenchymal stem/progenitor cells (MSPC) in the peripheral blood mono-nucleated cell population (FMD N= 16, Control N= 14). All data are expressed as the mean ± SEM.